Nodal marginal zone lymphoma

References

• Campo E, Pileri SA, Jaffe ES, et al. Nodal marginal zone lymphoma (NMZL). In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp 218–219.
   Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. CD5-monoclonal B-cell lymphoproliferation (MBL): clinical characteristics and outcome. Haematologica 2012;97(Suppl. 1): Abstract 215.
   Google Scholar
• Sheibani K, Sohn CS, Burke JS, et al. Monocytoid B-cell lymphoma. Am J Pathol 1986;124:310–318.
   PubMed Web of Science ®Google Scholar
• Cousar JB, McGinn DL, Glick AD, et al. Report of an unusual lymphoma arising from parafollicular B-lymphocytes (PBLS) or so-called “monocytoid” lymphocytes. Am J Clin Pathol 1987;87: 121–128.
   PubMed Web of Science ®Google Scholar
• Piris MA, Rivas C, Morente M, et al. Monocytoid B-cell lymphoma, a tumour related to the marginal zone. Histopathology 1988;12: 383–392.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Isaacson PG, Nathwani BN, Piris MA, et al. Nodal marginal zone lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., editors. Pathology and genetics: tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 161.
   Google Scholar
• Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2013;119:629–638.
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997;127:423–428.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Burcheri S, Rossi A, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007;18:346–350.
   PubMed Web of Science ®Google Scholar
• Kojima M, Tsukamoto N, Miyazawa Y, et al. Nodal marginal zone B-cell lymphoma associated with Sjögren's syndrome: a report of three cases. Leuk Lymphoma 2007;48:1222–1224.
   PubMed Web of Science ®Google Scholar
• Nathwani BBN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 1999;17:2486–2492.
   PubMed Web of Science ®Google Scholar
• Berger F, Felman P, Thieblemont C, et al. Non-malt marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950–1956.
   PubMed Web of Science ®Google Scholar
• Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003;27:762–771.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006;48:162–173.
   PubMed Web of Science ®Google Scholar
• Oh SY, Ryoo B-Y, Kim WS, et al. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 2006;85:781–786.
   Google Scholar
• Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. Cancer Sci 2007;98:44–49.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 2007;136:301–304.
   PubMed Web of Science ®Google Scholar
• Heilgeist A, McClanahan F, Ho AD, et al. Prognostic value of the follicular lymphoma international prognostic index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 2013;119:99–106.
   PubMed Web of Science ®Google Scholar
• Taddesse-Heath L, Pittaluga S, Sorbara L, et al. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 2003;27:522–531.
   PubMed Web of Science ®Google Scholar
• Nathwani BN, Mohrmann RL, Brynes RK, et al. Monocytoid B-cell lymphomas: an assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol 1992;23:1061–1071.
   PubMed Web of Science ®Google Scholar
• Petit B, Chaury MP, Le Clorennec C, et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica 2005;90:200–206.
   PubMed Web of Science ®Google Scholar
• Molina TJ, Lin P, Swerdlow SH, Cook JR. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol 2011;136:211–225.
   PubMed Web of Science ®Google Scholar
• Van den Brand M, van Krieken JHJM. Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. Haematologica 2013;98:1003–1013.
   PubMed Web of Science ®Google Scholar
• Aamot HV, Micci F, Holte H, et al. G-banding and molecular cytogenetic analyses of marginal zone lymphoma. Br J Haematol 2005;130:890–901.
   PubMed Web of Science ®Google Scholar
• Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-malt marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 2005;19:1818–1823.
   PubMed Web of Science ®Google Scholar
• Braggio E, Dogan A, Keats JJ, et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 2012;25:651–660.
   PubMed Web of Science ®Google Scholar
• Ferreira BI, García JF, Suela J, et al. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica 2008;93:670–679.
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996;87:299–307.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype- specific lesions with an impact on the clinical outcome. Blood 2011;117:1595–1604.
   PubMed Web of Science ®Google Scholar
• Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000;156: 1183–1188.
   PubMed Web of Science ®Google Scholar
• Baens M, Finalet Ferreiro J, Tousseyn T, et al. t(x;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica 2012;97:184–188.
   PubMed Web of Science ®Google Scholar
• Stary S, Vinatzer U, Mullauer L, et al. t(11;14)(q23;q32) involving IGH and DDX6 in nodal marginal zone lymphoma. Genes Chromosomes Cancer 2013;43:33–43.
   Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013;18:190–197.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25–30.
   PubMed Web of Science ®Google Scholar
• Novak U, Basso K, Pasqualucci L, et al. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol 2011;155:362–365.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Davi F, Simon EB, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica 2005;90:470–478.
   PubMed Web of Science ®Google Scholar
• Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001;98:781–786.
   PubMed Web of Science ®Google Scholar
• Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001;159:253–261.
   PubMed Web of Science ®Google Scholar
• Tierens A, Delabie J, Michiels L, et al. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 1999;93:226–234.
   PubMed Web of Science ®Google Scholar
• Traverse-Glehen A, Verney A, Baseggio L, et al. Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. Leukemia 2007;21:1821–1824.
   PubMed Web of Science ®Google Scholar
• Arribas AJ, Campos-Martín Y, Gómez-Abad C, et al. Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 2012;119:e9–e21.
   PubMedGoogle Scholar
• Baldini L, Brugiatelli M, Luminari S, et al. Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 2003;21:1459–1465.
   PubMed Web of Science ®Google Scholar
• Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010;34:184–189.
   PubMed Web of Science ®Google Scholar
• Kuper-Hommel MJJ, Van de Schans SAM, Vreugdenhil G, et al. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Leuk Lymphoma 2013; 54:1891–1897.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987–994.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Merli F, Luminari S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol 2011;90: 323–330.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2012;91:543–551.
   PubMed Web of Science ®Google Scholar
• Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009;145:741–748.
   PubMed Web of Science ®Google Scholar
• Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer 2012;118:3954–3961.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the STIL. Blood. 2010;116(Suppl. 1): Abstract 856.
   Google Scholar
• Oh SY, Kim WS, Lee DH, et al. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs 2010;28:171–177.
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003;21:1263–1270.
   PubMed Web of Science ®Google Scholar
• Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma 2004;45:315–320.
   PubMed Web of Science ®Google Scholar
• Li L, Bierman P, Vose J, et al. High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011;11:253–256.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346–3353.
   PubMed Web of Science ®Google Scholar
• Goy A, Leach J, Ehmann WC, et al. Inotuzumab ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trial. Blood 2010; 116(Suppl. 1): Abstract 430.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–684.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807–2812.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198–1203.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010;28:(15S Suppl.): Abstract 8036.
   Google Scholar
• Turner NC, Dusheiko G, Jones A. Hepatitis C and B-cell lymphoma. Ann Oncol 2003;14:1341–1345.
   PubMed Web of Science ®Google Scholar
• Chan CH, Hadlock KG, Foung SKH, et al. VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001;97:1023–1026.
   PubMed Web of Science ®Google Scholar
• Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23: 468–473.
   PubMed Web of Science ®Google Scholar